OcugenNASDAQ: OCGN

•  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial •  DSMB Determination to Proceed with High Dose Cohort Dosing

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.

NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ocugen securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period").

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.

LOS ANGELES , June 7, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Class Period: May 8, 2020 – April 1, 2024 Lead Plaintiff Deadline: June 10, 2024 If you wish to serve as lead plaintiff of the Ocugen lawsuit, you can submit your contact information at www.glancylaw.com/cases/Ocugen-Inc-1/.

NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ocugen securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period").

LOS ANGELES , June 6, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN).

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 10, 2024.